Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

11/7/24 10:25:46 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BCRX alert in real time by email

SC 13G/A 1 UnitedStates_13G__BioCrystPh.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* (Name of Issuer) BioCryst Pharmaceuticals Inc (Title of Class of Securities) Common Stock (CUSIP Number) 09058V103 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 09058V103 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 368,978 (7) Sole dispositive power 19,727,781 (8) Shared dispositive power 578,815 (9) Aggregate amount beneficially owned by each reporting person 20,306,596 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 9.81% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: BioCryst Pharmaceuticals Inc Item 1(b) Address of issuer's principal executive offices: 4505 Emperor Blvd Suite 200 Durham, NC 27703 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 09058V103 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 20,306,596 (b) Percent of class: 9.81% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 20,306,596 (b) Percent of class: 9.81% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 368,978 (iii) Sole power to dispose or to direct the disposition of: 19,727,781 (iv) Shared power to dispose or to direct the disposition of: 578,815 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, t* he securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer* of the securities and were not acquired and are not held in connection with or* as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 07, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration

Get the next $BCRX alert in real time by email

Recent Analyst Ratings for

$BCRX

Date	Price Target	Rating	Analyst
4/29/2025	$20.00	Overweight	Cantor Fitzgerald
2/25/2025	$15.00	Outperform	Wedbush
11/20/2023	$10.00	Overweight	JP Morgan
9/18/2023	$9.00 → $10.00	Sector Perform → Outperform	RBC Capital Mkts
8/4/2023	$11.00	Hold → Buy	Jefferies
7/13/2023	$10.00	Neutral → Buy	BofA Securities
2/22/2023	$14.00	Hold → Buy	Needham
11/2/2022	$14.00 → $16.00	In-line → Outperform	Evercore ISI

More analyst ratings

Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

Chat with this insight

Recent Analyst Ratings for $BCRX

$BCRX SEC Filings

BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

$BCRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on BioCryst Pharma with a new price target

Wedbush initiated coverage on BioCryst Pharma with a new price target

JP Morgan resumed coverage on BioCryst Pharma with a new price target

$BCRX Financials

Live finance-specific insights

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

BioCryst to Report First Quarter 2025 Financial Results on May 5

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

$BCRX Press Releases

Fastest customizable press release news feed in the world

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

$BCRX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Levin Alan G bought $49,996 worth of shares (7,861 units at $6.36), increasing direct ownership by 21% to 44,951 units (SEC Form 4)

Aselage Steve bought $16,000 worth of shares (2,500 units at $6.40) (SEC Form 4)

Hutson Nancy J bought $31,900 worth of shares (5,000 units at $6.38), increasing direct ownership by 6% to 86,818 units (SEC Form 4)

$BCRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Frank Steven was granted 1,866 shares (SEC Form 4)

SEC Form 3 filed by new insider Frank Steven

Chief R&D Officer Thackray Helen M. covered exercise/tax liability with 7,525 shares, decreasing direct ownership by 2% to 377,318 units (SEC Form 4)

$BCRX Large Ownership Changes

This live feed shows all institutional transactions in real time.